S. Hilsenbeck

W. Schwesinger, S. Hilsenbeck, S. Schenker, 2000, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Survival after first recurrence of breast cancer. The miami experience

S. Hilsenbeck, C. Vogel, S. Azevedo, 1992, Cancer.

Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells

S. Hilsenbeck, D. V. Von Hoff, S. Hilsenbeck, 1992, Anti-cancer drugs.

Comparison of three tumor markers--CA-125, lipid-associated sialic acid (LSA), and NB/70K--in monitoring ovarian cancer.

S. Hilsenbeck, H. Averette, E. Petru, 1990, Gynecologic Oncology.

Activity of 2, 2 -difluorodeoxycytidine (Gemcitabine) against human tumor colony forming units

S. Hilsenbeck, D. V. Von Hoff, S. Hilsenbeck, 1992, Anti-cancer drugs.

Phase II study of flutamide as second line chemotherapy in patients with advanced pancreatic cancer

S. Hilsenbeck, M. Rothenberg, C. Stephens, 2004, Investigational New Drugs.

Treatment of murine hepatic metastases with vaccinia colon oncolysates and IL-2.

S. Hilsenbeck, M. Wallack, H. Iwaki, 1988, The Journal of surgical research.

Hypothyroidism after craniospinal irradiation with proton or photon therapy in patients with medulloblastoma

S. Hilsenbeck, M. Chintagumpala, A. Mahajan, 2018, Pediatric hematology and oncology.

The Increasing Recognition of Adenosquamous Lung Carcinoma (1977–1986)

S. Hilsenbeck, K. Sridhar, R. Duncan, 1992, American journal of clinical oncology.

Five-drug antiemetic combination for cisplatin chemotherapy.

S. Hilsenbeck, V. Cairns, K. Sridhar, 1992, Cancer investigation.

Microinvasive carcinoma of the cervix

S. Hilsenbeck, M. Nadji, B. Sevin, 1992, Cancer.

Prevalence of Cryptosporidium parvum infection in children along the Texas-Mexico border and associated risk factors.

S. Hilsenbeck, C. Leach, F. Koo, 2000, The American journal of tropical medicine and hygiene.

Human Tumor Screening

S. Hilsenbeck, D. D. Hoff, A. Hanauske, 2004 .

Preclinical activity of taxotere (RP 56976, NSC 628503) against freshly explanted clonogenic human tumour cells: comparison with taxol and conventional antineoplastic agents.

C. Fellbaum, M. Aapro, H. Nekarda, 1993, European journal of cancer.

A phase I and pharmacokinetic trial of terephthalamidine (NSC 57155) as a 120-hour continuous infusion

G. Weiss, D. V. Von Hoff, G. Clark, 1998, Investigational New Drugs.

Loss of heterozygosity at D14S62 and metastatic potential of breast cancer.

P. O’Connell, S. Fuqua, D. Allred, 1999, Journal of the National Cancer Institute.

A fully Bayesian latent variable model for integrative clustering analysis of multi-type omics data.

Marina Vannucci, Cui Guo, Ronglai Shen, 2018, Biostatistics.

Pathological features and BRCA1 mutation screening in premenopausal breast cancer patients.

J. Sng, S. Hilsenbeck, J. Chang, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Endoscopic assessment of radiological stage IVA cervical cancer: A bivariate meta-analysis supporting an evidence-based staging algorithm proposal.

S. Hilsenbeck, T. Showalter, E. Jo, 2022, Gynecologic oncology.

Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer.

S. Hilsenbeck, G. Clark, C. Osborne, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

Prognostic factors of early stage cervical cancer treated by radical hysterectomy

Ying-jv Lu, S. Hilsenbeck, M. Nadji, 1995, Cancer.

Clinical trial of high‐dose oral medroxyprogesterone acetate in the treatment of metastatic breast cancer and review of the literature

S. Hilsenbeck, V. Cairns, C. Vogel, 1988, Cancer.

Congenital Anomalies and Anthropometry of 42 Individuals with Deletions of Chromosome 18q

S. Hilsenbeck, D. Hale, C. Kaye, 1999, American journal of medical genetics.

Incidence and hospital stay for cardiac and pulmonary complications after abdominal surgery

C. Mulrow, V. Lawrence, S. Hilsenbeck, 1995, Journal of General Internal Medicine.

Risk of pulmonary complications after elective abdominal surgery.

V. Lawrence, S. Hilsenbeck, C. P. Page, 1996, Chest.

Postoperative complications after thoracic and major abdominal surgery in patients with and without obstructive lung disease.

V. Lawrence, K. Kroenke, S. Hilsenbeck, 1993, Chest.

The epidemiology of viral hepatitis in children in South Texas: increased prevalence of hepatitis A along the Texas-Mexico border.

S. Hilsenbeck, C. Leach, F. Koo, 1999, The Journal of infectious diseases.

Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients

N. Brünner, G. Clark, S. Hilsenbeck, 1997, Breast Cancer Research and Treatment.

Modernizing Eligibility Criteria for Molecularly Driven Trials.

Edward S. Kim, R. Schilsky, K. Hunt, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.

D. V. Von Hoff, S. Hilsenbeck, H. Burris, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The small heat shock protein HSP27 is not an independent prognostic marker in axillary lymph node-negative breast cancer patients.

S. Hilsenbeck, S. Fuqua, D. Allred, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

Synergistic effects of taxol/taxotere on radiation sensitivity on human tumor cell lines

H. Choy, S. Hilsenbeck, D. D. Hoff, 1992 .

Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model.

E K Rowinsky, S G Hilsenbeck, D. V. Von Hoff, 1999, Cancer research.

Congenital anomalies and anthropometry of 42 individuals with deletions of chromosome 18q.

S. Hilsenbeck, D. Hale, C. Kaye, 1999 .

Preclinical activity of ilmofosine against human tumor colony forming units in vitro

S. Hilsenbeck, A. Hanauske, J. Mcphillips, 1992, Anti-cancer drugs.

Combination anti-Aβ treatment maximizes cognitive recovery and rebalances mTOR signaling in APP mice

S. Hilsenbeck, J. Cirrito, J. Jankowsky, 2018, The Journal of experimental medicine.

Evidence of enhanced in vivo activity using tirapazamine with paclitaxel and paraplatin regimens against the MV-522 human lung cancer xenograft

D. V. Von Hoff, S. Hilsenbeck, G. Mangold, 1999, Cancer Chemotherapy and Pharmacology.

Prognostic value of p53 for local failure in mastectomy-treated breast cancer patients.

R. Zellars, R. Elledge, D. Allred, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mitosin (a new proliferation marker) correlates with clinical outcome in node-negative breast cancer.

D. Allred, W. Lee, G. Clark, 1997, Cancer research.

MGI 114: augmentation of antitumor activity when combined with topotecan.

D. V. Von Hoff, S. Hilsenbeck, J. Marty, 2000, Journal of pediatric hematology/oncology.

Significance of axillary lymph node metastasis in primary breast cancer.

S G Hilsenbeck, G M Clark, I. Jatoi, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Significance o f A xillary L ymph N ode M etastasis in P rimary B reast C ancer

C. Osborne, I. Jatoi, G. Clark, 1999 .

A prospective study of a simple algorithm to individually dose high-dose methotrexate for children with leukemia at risk for methotrexate toxicities

S. Hilsenbeck, E. Jo, M. Scheurer, 2018, Cancer Chemotherapy and Pharmacology.

Radiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy.

R. Elledge, G. Clark, P. Ravdin, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rising levels of estrogen receptor in breast cancer over 2 decades.

R. Elledge, G. Chamness, S. Hilsenbeck, 1994, Cancer.

Outcomes Among Minority Patients With Metastatic Colorectal Cancer in a Safety-net Health Care System.

S. Hilsenbeck, A. Thrift, E. Jo, 2020, Clinical colorectal cancer.

Cross-species identification of a plasma microRNA signature for detection, therapeutic monitoring, and prognosis in osteosarcoma

L. Donehower, C. Ahern, S. Hilsenbeck, 2015, Cancer medicine.

The prognostic significance of surgical staging for carcinoma of the endometrium.

A. Markoe, S. Hilsenbeck, J. Schwade, 1992 .

Optimal mastectomy timing.

S. Hilsenbeck, G. Clark, W L McGuire, 1992, Journal of the National Cancer Institute.

Estimation of completeness and adjustment of age-specific and age-standardized incidence rates.

S G Hilsenbeck, C Kurucz, R C Duncan, 1992, Biometrics.

Effects of Recombinant Human Interleukin‐1α on Clonogenic Growth of Primary Human Tumors In Vitro

S. Hilsenbeck, P. Banks, D. D. Hoff, 1992, Journal of immunotherapy : official journal of the Society for Biological Therapy.

Value of 8S/4S fractionation of estrogen receptors (ER) for prediction of response to hormonal manipulation in metastatic breast cancer

S. Hilsenbeck, C. Vogel, S. Thomsen, 1984, Breast Cancer Research and Treatment.

Genomic profiling of plasmablastic lymphoma using array comparative genomic hybridization (aCGH): revealing significant overlapping genomic lesions with diffuse large B-cell lymphoma

E. Jaffe, C. Creighton, Yongdong Feng, 2009, Journal of hematology & oncology.

Lack of prognostic value of cathepsin D levels for predicting short term outcomes of breast cancer patients.

G. Clark, P. Ravdin, S. Hilsenbeck, 1997, Cancer letters.

POSITIVELY AGING: CHOICES AND CHANGES CREATING INTERDISCIPLINARY MIDDLE SCHOOL TEACHING MATERIALS USING EXAMPLES FROM GERIATRICS AND GERONTOLOGY

S. Hilsenbeck, Shuko Lee, M. Lichtenstein, 1999 .

Association of Surgery With Improved Survival in Stage IV Breast Cancer Patients

S. Hilsenbeck, R. Elledge, S. Hilsenbeck, 2008, Annals of surgery.

Preoperative spirometry and laparotomy: blowing away dollars.

V. Lawrence, S. Hilsenbeck, C. P. Page, 1997, Chest.

Difluoromethylornithine Plus Sulindac for the Prevention of Sporadic Colorectal Adenomas: A Randomized Placebo-Controlled, Double-Blind Trial

Edward S. Kim, Diane D. Liu, N. Colburn, 2008, Cancer Prevention Research.

p53 is mutated in a subset of advanced-stage prostate cancers.

S. Hilsenbeck, D. Allred, S. Hilsenbeck, 1993, Cancer research.

Long-term survival in stage III and IV ovarian cancer

S. Hilsenbeck, B. Sevin, H. Averette, 2006, Archives of Gynecology and Obstetrics.

Making the most of your prognostic factors: Presenting a more accurate survival model for breast cancer patients

Teri Oldaker, M. Pandian, G. Clark, 2005, Breast Cancer Research and Treatment.

Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival.

S. Hilsenbeck, D. Yee, S. Hilsenbeck, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Breast Cancer Research and Treatment 2001 Reviewers

D. Berry, L. Holmberg, D. Alberts, 2004, Breast Cancer Research and Treatment.

Downregulation of calcitonin receptor mRNA expression by calcitonin during human osteoclast-like cell differentiation.

S. Hilsenbeck, S. Hilsenbeck, S. Goldring, 1995, The Journal of clinical investigation.

Effect of BioGlue® on the Incidence of Pancreatic Fistula Following Pancreas Resection

S. Hilsenbeck, S. Hilsenbeck, W. Fisher, 2008, Journal of Gastrointestinal Surgery.

Comparative efficacy of short‐term versus long‐term cefoxitin prophylaxis against postoperative infection after radical hysterectomy: A prospective study

S. Hilsenbeck, B. Sevin, L. Guerra, 1991, Obstetrics and gynecology.

BRCA1 in clinical breast cancer.

C. Osborne, R. Elledge, S. Hilsenbeck, 1998, Breast disease.

Rising levels of estrogen receptor in breast cancer over 2 decades

R. Elledge, G. Chamness, S. Hilsenbeck, 1994, Cancer.

Toxicity of FED Chemotherapy in Non‐small‐Cell Lung Cancer

S. Hilsenbeck, G. Fountzilas, R. Thurer, 1987, American journal of clinical oncology.